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Human Calmodulin Mutations
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Fluxes of calcium (Ca2+) across cell membranes enable fast cellular responses.
Calmodulin (CaM) senses local changes in Ca2+ concentration and relays the
information to numerous interaction partners. The critical role of accurate Ca2+ signaling
on cellular function is underscored by the fact that there are three independent CaM
genes (CALM1-3) in the human genome. All three genes are functional and encode
the exact same CaM protein. Moreover, CaM has a completely conserved amino acid
sequence across all vertebrates. Given this degree of conservation, it was long thought
that mutations in CaM were incompatible with life. It was therefore a big surprise when
the first CaM mutations in humans were identified six years ago. Today, more than a
dozen human CaM missense mutations have been described, all found in patients with
severe cardiac arrhythmias. Biochemical studies have demonstrated differential effects
on Ca2+ binding affinities for these CaM variants. Moreover, CaM regulation of central
cardiac ion channels is impaired, including the voltage-gated Ca2+ channel, CaV1.2,
and the sarcoplasmic reticulum Ca2+ release channel, ryanodine receptor isoform 2,
RyR2. Currently, no non-cardiac phenotypes have been described for CaM variant
carriers. However, sequencing of large human cohorts reveals a cumulative frequency
of additional rare CaM mutations that raise the possibility of CaM variants not exclusively
causing severe cardiac arrhythmias. Here, we provide an overview of the identified
CaM variants and their known consequences for target regulation and cardiac disease
phenotype. We discuss experimental data, patient genotypes and phenotypes as well
as which questions remain open to understand this complexity.
Keywords: calmodulin, cardiac arrhythmia, calmodulinopathy, CPVT, LQTS, CALM1, CALM2, CALM3
INTRODUCTION
For generations, a large Swedish family presented with repeated episodes of syncope and cardiac
arrest in response to exercise or emotional stress. Several family members were diagnosed with the
inherited disorder catecholaminergic polymorphic ventricular tachycardia (CPVT), which is often
fatal due to a high risk of ventricular fibrillation and sudden cardiac death (SCD). Indeed, two of
the 13 affected individuals died from SCD, both at a young age. In 2012, we linked the disease
to a mutation in the gene CALM1, which encodes the calcium (Ca2+) sensor calmodulin (CaM)
(Nyegaard et al., 2012). The identification of a human CaM missense mutation came as a dramatic
surprise to the CaM research field; CaM is exceptionally conserved across species with all vertebrate
Abbreviations: AP, action potential; CaM, calmodulin; CaV, voltage-gated calcium channel; CDI, calcium-dependent
inactivation; CPVT, catecholaminergic polymorphic ventricular tachycardia; IVF, idiopathic ventricular fibrillation; LQTS,
long QT syndrome; RyR2, ryanodine receptor isoform 2; SCD, sudden cardiac death; SR, sarcoplasmic reticulum.
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CALM genes encoding identical proteins, and human mutations
had not previously been reported. The slow evolution of
CaM emphasizes the strong selection pressure against even
minor changes in the protein sequence (Halling et al., 2016).
Further, CaM regulates more than 300 intracellular targets, each
interaction with unique facets of binding sites, Ca2+-dependency,
target affinity, and functionality (Shen et al., 2005; O’Connell
et al., 2010). With this versatility in mind, it was believed that
mutations in CaM could not be tolerated.
After our initial finding, a number of CaM mutations have
been identified in patients with severe cardiac arrhythmia
disorders involving recurrent syncope, ventricular fibrillation,
and in some instances SCD under adrenergic stimulation
(Table 1). The vast majority of these mutations are de novo
and carriers present with disease phenotypes early or very early
in childhood, in some cases even before birth. In addition
to CPVT, carriers suffer from long QT syndrome (LQTS),
and one individual was diagnosed with idiopathic ventricular
fibrillation (IVF). The link between CaM mutations and these
arrhythmias has primarily been attributed to impaired regulation
of the cardiac ryanodine receptor isoform 2 (RyR2), and the
cardiac L-type voltage gated Ca2+ channel isoform 1.2 (CaV1.2)
(Table 1).
Since CaM is encoded by three active genes and expressed
in all cells, the CaM field is faced with intriguing questions and
paradoxes at the genetic and phenotypic level. First, how can a
single mutation in one of six CaM-encoding alleles dominantly
cause SCD? Second, how can identical missense mutations
cause LQTS in one patient and CPVT in another? Third, with
an increasing number of new rare CaM missense mutations
identified in sequencing databases of large human cohorts, could
there be other phenotypes associated with CaM mutations?
Improved understanding of the functional impact of CaM
mutations may enable predictions of the genotype–phenotype
relationship for variants in any of the three CALM genes.
In this review, we summarize and discuss the current
knowledge on CaM mutations and their impact on the regulation
of CaV1.2 and RyR2, and address the few studies that suggest
an involvement of other targets. Finally, we discuss the special
genetic context of CaM and the implications for future studies.
CaM, THE CELLULAR Ca2+ SENSING
PROTEIN
Fast and compound changes in cytosolic Ca2+ concentration is
the foundation for a wide number of cellular responses, including
muscle contraction and neuronal firing (Clapham, 2007). Thus, at
rest, the cytosolic Ca2+ concentration is maintained at∼100 nM,
but can rapidly increase to more than 100 µM, when Ca2+
channels open in the plasma membrane or in internal stores such
as the sarcoplasmic reticulum (SR). Detection of this steep change
in Ca2+ concentration depends on Ca2+ binding proteins. CaM
is one of the major Ca2+ sensors that relay information on Ca2+
concentration to functionally modulate target proteins (known as
calmodulation). CaM is synthesized as a 149 amino acid protein,
however, the initiator Met residue is removed upon translation,
leaving 148 amino acid residues in the mature protein (Sasagawa
et al., 1982). This has led to some confusion in the numbering of
CaM variant positions. The Human Genome Variant Sequence
(HGVS) nomenclature (den Dunnen et al., 2016) recommends
to count the initiator Met as residue number 1, while the CaM
protein community tends to leave the residue out as it has no
functional role in the mature protein. Throughout this paper we
will use the HGVS nomenclature.
The structure of CaM reflects its refined Ca2+ sensing abilities
(Kretsinger et al., 1986; Chattopadhyaya et al., 1992). CaM is
a 16.7 kDa protein consisting of two lobes connected by a
flexible and unstructured or α-helical linker (Figures 1A,B).
Each lobe has two EF-hands, which can each coordinate
one Ca2+ ion (Figures 1A,B, gray spheres). The C-terminal
lobe of CaM binds Ca2+ with six times higher affinity (KD
2.5 µM) than the N-terminal lobe (KD 16 µM), allowing
CaM to sense Ca2+ across a wide concentration range (Linse
et al., 1991; Søndergaard et al., 2015a). Hydrophobic patches
on the inside of each lobe recognize binding motifs on
interaction partners, and thereby facilitate CaM binding and
target regulation (Tidow and Nissen, 2013). Ca2+ binding
to CaM and CaM binding to target proteins allosterically
affect the affinity of each other, and targets specifically
modulate the conformation of CaM. In this way, the small
CaM protein displays a plethora of binding and regulation
properties.
CaM CONSERVATION AND MUTATIONS
Despite the remarkable conservation of CaM, 26 cases of
arrhythmogenic mutations have now been identified in humans.
Their positions in CaM are indicated on a CaM structure in
Figure 1A and on the CaM sequence in Figure 1C. Strikingly,
the mutations are primarily found in the C-terminal lobe and
most affect residues involved in Ca2+ coordination, dramatically
reducing Ca2+ affinity (Table 1). One interesting exemption
is the mutation initially identified in the large Swedish family,
CaM-N54I. This mutation is unique since it (1) resides in the
N-terminal lobe and (2) neither coordinates Ca2+ nor is part of
the hydrophobic target binding patches. Biochemical and cellular
experiments have been employed to model and explain how CaM
mutations lead to arrhythmic phenotypes. The results from these
studies are discussed in the following.
CaM Mutations Disturb Heart Rhythm
The composite effect of CaM mutations on heart function has
been investigated using different experimental model systems.
In zebrafish, the CaM-N54I and -N98S mutations caused
increased heart rate upon β-adrenergic stimulation, which is
in line with the CPVT phenotype observed for patients with
these mutations (Søndergaard et al., 2015a). Similarly, the
LQTS-mutation D130G increased zebrafish heart rate (Berchtold
et al., 2016). In cultures of ventricular cardiomyocytes, expression
of LQTS-associated CaM mutations leads to prolonged action
potentials (APs), in some cases spilling over to the next
stimulation and causing alternans (Limpitikul et al., 2014, 2017;
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Gomez-Hurtado et al., 2016; Yamamoto et al., 2017). Moreover,
CaM-D96V was associated with early after-depolarizations
(Gomez-Hurtado et al., 2016). Imaging of Ca2+ fluxes during
electrical pacing of cardiomyocytes demonstrated dysregulated
Ca2+ concentration in cells expressing LQTS-associated CaM-
D96V, -D130G, -F142L, and in particular the CPVT-mutation
N54I showed Ca2+ overload, Ca2+ reuptake errors, or alternans
(Limpitikul et al., 2014, 2017; Yin et al., 2014).
CaV1.2 and RyR2 are the two major Ca2+ channels involved
in Ca2+ handling in the heart. Both channels are essential for
stimulating – and importantly, terminating – heart contraction.
Briefly, APs stimulate the opening of CaV1.2 in the sarcolemma.
This allows Ca2+ to enter the cell. The resulting increase in
cytosolic Ca2+ stimulates opening of RyR2, thereby releasing
large amounts of Ca2+ from the SR which ultimately leads
to heart contraction (Sorensen et al., 2013). CaM binds to
both CaV1.2 and RyR2 and is important for the precise and
timely gating of the channels in response to changes in Ca2+
concentration. Generally, CPVT is an SR Ca2+ handling disease,
most often caused by RyR2 mutations, whereas LQTS involves
dysregulation of ion-fluxes across the sarcolemma, e.g., Ca2+ flux
disturbances caused by mutations in CaV1.2 (Landstrom et al.,
2017).
Impaired Regulation of CaV1.2
CaM is tethered to the intracellular C-terminal tail of CaV1.2 and
functions as a Ca2+ sensor to stimulate channel closure when
Ca2+ has entered the cell, a process termed calcium-dependent
inactivation (CDI) (Brehm and Eckert, 1978; Peterson et al.,
1999). Reduction of CDI was observed for several LQTS-causing
CaM mutations, including D132H, D132V, and E141G (Boczek
et al., 2016; Pipilas et al., 2016), whereas CDI was completely
absent for LQTS-associated CaM mutations D96V, D130G, and
F142L in HEK293 cells and adult guinea pig cardiomyocytes
(Limpitikul et al., 2014). The CaM-N98S mutation is special in
the sense that carriers display either CPVT or LQTS arrhythmias
or both. Expression of this mutant slightly reduces CDI of
CaV1.2, whereas the strictly CPVT-causing mutation CaM-N54I
showed no effect (Limpitikul et al., 2014; Yamamoto et al.,
2017).
Effects of CaM Mutations on RyR2
RyR2 opening is normally stimulated by the increase in Ca2+
upon CaV1.2 opening. In response to the dramatic increase
in cytoplasmic Ca2+ concentration (and the drop in SR
luminal Ca2+ concentration), RyR2 closes. CaM acts as a
gatekeeper, by modulating the open state probability of RyR2
in response to changes in the Ca2+ concentration (Fabiato,
1985; Xu and Meissner, 2004). Here, we have compiled the
diverse experimental approaches used to evaluate whether
CaM mutations affect RyR2 regulation under different Ca2+
concentrations (Table 1). The results are mixed and in some
cases contradictory. The CPVT-associated CaM mutations, N54I,
N98S, and A103V, all showed an increased level of RyR2
opening, that is, decreased inhibition by CaM (Hwang et al.,
2014; Søndergaard et al., 2015b; Gomez-Hurtado et al., 2016).
These results suggest that the molecular disease mechanism for
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the CPVT-causing CaM mutations is dysregulation of cardiac
SR Ca2+ release, in line with CPVT-causing mutations in
RyR2.
Surprisingly, LQTS-associated CaM mutations also caused
differences in RyR2 binding and regulation (Hwang et al., 2014;
Søndergaard et al., 2015b; Vassilakopoulou et al., 2015). However,
in particular at low Ca2+ concentrations, the data are somewhat
contradictory (Table 1). Curiously, CaM-F142L showed an
increased binding affinity toward RyR2 in the apo-form, as well
as an increased inhibitory effect on RyR2 in some assays, an effect
opposite of all other CaM mutants analyzed (Søndergaard et al.,
2017).
Other Suggested and Potential Targets
Although mutations in CaV1.2 can lead to LQTS, most cases
of LQTS can be attributed to mutations in genes encoding
the voltage-gated K+ channels KV7.1 (KCNQ1) and KV11.1
(KCNH2), as well as the voltage-gated Na+ channel NaV1.5
(SCN5A) (Modell and Lehmann, 2006). Although regulated
by CaM, no clear effects of CaM mutations have been
observed on NaV1.5 (Yin et al., 2014; Boczek et al., 2016;
Rocchetti et al., 2017). KV7.1 utilizes CaM as a sensor of
Ca2+ to stimulate opening (Ghosh et al., 2006). Whereas
CaM-F142L did not show any effect on KV7.1 current (IKs)
(Rocchetti et al., 2017), CaM-N98S significantly shifted the
half-activation of KV7.1 (Sun and MacKinnon, 2017). Further,
the small-conductance Ca2+-activated K+ (SK) channel was
decreased by several CaM mutations (Yu et al., 2016). Although
SK channels play a minor role in ventricular myocytes,
they are expressed in atrial myocytes, and interestingly,
widely expressed in the nervous system where they play
a major role in synaptic transmission (Adelman et al.,
2012).
Ca2+/CaM-dependent kinase II (CaMKII) regulates a wide
number of pathways and protein targets, but no significant effects
were observed on CaMKII with either of the CaM variants N54I,
D96V, N98S, D130G, or F142L (Hwang et al., 2014; Berchtold
et al., 2016).
Although current literature suggests that Ca2+ channels are
the main targets affected by CaM mutations, we hypothesize
that other ion channels and potentially other signaling proteins
may also be dysregulated if tested in greater detail. But how can
one predict which targets are likely affected by CaM mutations?
We believe that the Ca2+-dependency of target binding plays
an important role. That is, proteins that bind to both the
apo- and the Ca2+-form of CaM may be more sensitive to
mutations in CaM than targets that only bind the Ca2+-form.
Thus, CaM mutations may exert a dominant effect in cases
where CaM remains associated with its target when the cell is at
rest.
IMPLICATIONS OF THE GENETIC
ARCHITECTURE OF CALM GENES
In humans, CaM is encoded by three different and independent
loci; on chromosome 2 (CALM2), 14 (CALM1), and 19 (CALM3).
Although there are differences in the genomic sequence, the three
different transcripts are translated into the exact same protein
(Fischer et al., 1988). During the last six years (2012–2018),
26 cases of pathogenic mutations in CaM have been reported,
and all three CALM genes are now established major genes for
both CPVT and LQTS (Table 1). All identified pathogenic CaM
mutations cluster in the C-lobe, except the CPVT-causing variant
N54I. Interestingly, this is the mutation with the mildest effect on
biophysical parameters of CaM, including Ca2+ binding affinity.
It is also the only variant found in a large family. Further, all
LQTS-causing CaM mutations strongly reduce the C-lobe Ca2+
affinity, and, except for the F142L mutation, are all located in
Ca2+-coordinating residues. This suggests that CaM mutations
that strongly affect C-lobe Ca2+ affinity lead to LQTS (Table 1).
To date, there are more published cases of pathogenic
mutations in CALM1 (11) and CALM2 (11) compared to CALM3
(4). This could either reflect that the first published mutations
were found in CALM1 and CALM2 and thus these two genes were
included in genetic screening panels before CALM3. Or, it may
be due to some subtle functional differences between the three
genes. Quantitative PCR have shown that the three genes are not
expressed at equal levels in cardiomyocytes, but the relative levels
are not clear: whereas one study found higher levels of CALM3
transcripts in human hearts (Crotti et al., 2013), the CALM1
transcript was the most abundant in human stem cell-derived
cardiomyocytes (Rocchetti et al., 2017).
As the number of published pathogenic CaM mutations
has increased, several conclusions about genotype–phenotype
relationships begin to form. Of particular interest is the
CaM-D130G mutation, which has been identified in four
unrelated individuals; two carrying the mutation in CALM1,
one in CALM2, and one in CALM3, and all four suffering from
LQTS. Similarly, the CaM-F142L mutation was found in both
CALM1 and CALM3, and all carriers suffered from LQTS. These
observations imply that the amino acid position and type of
change is important for the phenotype, and not the genetic
origin of the transcript (CALM1, −2, or −3). One intriguing
observation does, however, challenge this simple genotype–
phenotype conclusion. The CaM-N98S mutation was found in
CALM1 in one individual, and in three other individuals in
CALM2. Interestingly, these four patients present with different
phenotypes – either CPVT or LQTS or both – suggesting that
we still do not fully understand the underlying mechanisms
determining the disease phenotype. These may involve other
genomic variants able to shape the phenotype, complex protein
regulatory effects, or environmental factors.
Since the protein products from all CALM genes are
identical, it is tempting to speculate if a deletion of one allele
(equivalent to a loss-of-function mutation) is less pathogenic
than missense mutations. This idea immediately poses a
therapeutic solution to patients carrying a CaM missense
mutation, for example using the CRISPR/Cas9 technology to
delete the pathogenic allele. Two studies specifically silenced the
mutated CaM allele in patient-derived pluripotent stem cells
differentiated into cardiomyocytes. Here, the CaM-D130G and -
N98S mutations were silenced in CALM2 with a partial or almost
full restoration of CaV1.2 regulation (Limpitikul et al., 2017;
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Yamamoto et al., 2017). These experiments are proof-of-principle
that removal of the diseased allele may be a therapeutic solution.
Also, these studies suggest that potential frameshift mutations
causing premature stop codons or protein degradation may not
be as detrimental as missense mutations. It still needs to be
determined, however, if individuals carrying a loss-of-function
mutation in a CALM gene are in fact unaffected from disease.
Interestingly, a large exome sequencing study [Exome Aggregate
Consortium (ExAC)] (Lek et al., 2016), found that CALM1 and
CALM2 are intolerant to loss-of-function mutations (pLI = 0.89
and 0.86 respectively).
DIGGING DEEPER MAY REVEAL A
BROADER IMPACT
Given the ubiquitous role of CaM, it is striking that all mutations
identified are associated with a strong cardiac phenotype. We
speculate whether these cases were discovered because of their
unusual severity and because cardiologists and geneticists have
specifically screened for CALM mutations in populations with
cardiac disorders. Looking for CaM mutations in other patient
groups may reveal new aspects and consequences of these
mutations.
In a database containing variants from a large sequencing
effort of almost 140,000 individuals (GnomAD, Lek et al.,
2016), additional rare CaM missense mutations are reported
(Figures 1B,C, gray residues and circles). The number of coding
variants for all three genes is much lower than expected by
chance. However, the cumulative frequency of additional rare
CaM mutations suggests that CaM variants do not exclusively
cause severe cardiac arrhythmias. At present, there is no overlap
between variants identified in GnomAD (database variants)
and the published pathogenic mutations. Further, the GnomAD
missense variants are distributed throughout the entire protein,
and more evenly distributed on the three CALM genes (9,
9, and 12 mutations in CALM1, −2, and −3, respectively),
compared to the arrhythmogenic CaM variants. Also, all
GnomAD variants except two, fall outside Ca2+-coordinating
residues. Taken together, we therefore speculate that some of
these uncharacterized variants are associated with unknown traits
not involving cardiac arrhythmia. Sequencing results from large
cohorts with known phenotypes are required to confirm this
hypothesis.
We propose that studies of tissues other than cardiac are
warranted for future research on the effects of CaM mutations.
In particular, CaM expression is high in excitable neuronal cells.
Also CaV1.2 is widely expressed in neuronal tissues. Here, CaV1.2
plays a role in cellular firing as well as in gene regulation, and
mutations in CaV1.2 have been attributed to psychiatric diseases
(Nyegaard et al., 2010; Nanou and Catterall, 2018). Neurons
express a number of other CaV channel isoforms, including
CaV1.3 and CaV2 variants, which are also regulated by CaM.
RyR2 plays a less prominent role in neurons, where the inositol
triphosphate receptor (IP3R), which is also regulated by CaM, is
the dominating intracellular Ca2+ release channel. Mild neuronal
defects have been observed in some patients with CaM mutations,
but these effects were suggested to be secondary, resulting from
the frequent and severe episodes of syncope or cardiac arrest
(Crotti et al., 2013; Boczek et al., 2016; Pipilas et al., 2016).
CONCLUSION AND OUTLOOK
Within the last six years, CaM mutations have emerged as
a novel cause of human diseases, the calmodulinopathies. All
described pathogenic mutations have been identified in patients
suffering from severe arrhythmic disorders, and biochemical
as well as cellular studies have demonstrated that particularly
the regulation of the Ca2+ channels CaV1.2 and RyR2 are
affected by these mutations. Currently, there is a strong
correlation between LQTS-causing CaM mutations and Cav1.2
dysregulation, whereas all mutations affect RyR2 function. Given
the ubiquitous role of CaM in a vast number of cellular processes,
we predict that yet other targets may be affected. Our database
search revealed a number of uncharacterized CaM missense
mutations with unknown phenotypic consequences present in
the population. Future studies will reveal whether other protein
targets as well as other disease phenotypes can be assigned to
mutations in CaM.
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